{"favorite_id": 10378, "calc_type": "", "dosing": false, "full_title_en": "Immune-Related Adverse Events for Renal Toxicities - Nephritis", "short_title_en": "IRAE for Renal Toxicities - Nephritis", "medium_description_en": "Grades severity of nephritis secondary to immune checkpoint inhibitor therapy.", "short_description_en": "Nephritis severity (ICPi therapy).", "before_use": "", "instructions_en": "<p>Use in adult patients with elevations in creatinine levels or symptoms suggesting nephritis while on treatment with immune checkpoint inhibitors.</p>", "purpose_en": ["Diagnosis", "Prognosis"], "disease_en": ["Nephritis"], "specialty_en": ["Allergy and Immunology", "Hospitalist Medicine", "Internal Medicine", "Nephrology"], "chief_complaint_en": ["Abdominal Pain", "Dysuria", "Hematuria", "Pain"], "system_en": ["Renal"], "search_abbreviation_en": ["Immune Related Adverse Events, irae, nephritis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"], "slug": "immune-related-adverse-events-renal-toxicities-nephritis", "seo": {"meta_description_en": "The Immune-Related Adverse Events for Renal Toxicities - Nephritis grades severity of nephritis secondary to immune checkpoint inhibitor therapy.", "keywords_en": "Immune Related Adverse Events, irae, nephritis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"}, "content": {"how_to_use": {"use_case_en": "<p>Adult patients with elevations in creatinine levels or symptoms suggesting nephritis that developed while on treatment with immune checkpoint inhibitors including agents against PD-1 (i.e. pembrolizumab, nivolumab), PD-L1 (i.e. atezolizumab, avelumab, durvalumab), or CTLA-4 (i.e. ipilimumab).</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-a8ce4840-7fff-77be-9fe6-3bba96803f0a\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) nephritis should be suspected in patients with elevations in creatinine levels or symptoms suggesting nephritis while on treatment with immune checkpoint inhibitors.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) nephritis is an uncommon but potentially serious toxicity.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">More frequently seen with combination treatment of more than one ICPi but is also an important adverse event caused by single agent ICPi.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">ICPi therapy appears to be safe in patients with baseline renal impairment from nonimmune basis (i.e. prior nephrectomy, old age, hypertension).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Management of ICPi nephritis is based on the grade of nephritis.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-5ce2b588-7fff-2210-e053-3e4e73c9e75e\">This tool aids in the decision of immune checkpoint inhibitor discontinuation, further diagnostic work-up and immunosuppressant treatment initiation.</p>"}, "next_steps": {"advice_en": "<p>Monitor patients for elevated serum creatinine prior to every dose.&nbsp;</p>\n<p>For suspected ICPi nephritis, consider holding therapy while other potential causes are evaluated (i.e. recent IV radiographic contrast administration, dehydration, other medicines, urinary tract infections) and monitor creatinine weekly.</p>\n<p>Routine urinalysis is not necessary other than to rule out urinary tract infections, etc.</p>\n<p>Presume ICPi nephritis for patients without other obvious causes or for those who do not respond to alternative treatment measures.</p>\n<p>If no potential alternative cause of acute kidney injury (AKI) is identified, then consider biopsy and proceed directly with immunosuppressive therapy.</p>", "management_en": "<p dir=\"ltr\">For all patients where an IRAE diagnosis is being considered, it is always recommended to involve the specialist or team prescribing the immune checkpoint therapy.&nbsp;</p>\n<p dir=\"ltr\"><strong>All patients:</strong></p>\n<p dir=\"ltr\">Monitor creatinine weekly.</p>\n<p dir=\"ltr\">Kidney biopsy should be discouraged until corticosteroid treatment has been attempted.</p>\n<p dir=\"ltr\"><strong>Grade 1:&nbsp;</strong></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider temporarily holding ICPi, pending consideration of potential alternative etiologies (recent IV contrast, medications, fluid status) and baseline renal function.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">A change that is still &lt;1.5 ULN could be meaningful.</p>\n</li>\n</ul>\n<p dir=\"ltr\"><strong>Grade 2:</strong></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Hold treatment temporarily.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider nephrology consultation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Evaluate for other causes (recent IV contrast, medications, fluid status, etc). If other etiologies are ruled out, administer 0.5-1 mg/kg/d prednisone equivalents.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If worsening or no improvement, consider 1-2 mg/kg/d prednisone or equivalent and permanently discontinue ICPi.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If improved to &le; Grade 1, taper corticosteroids over 4-6 weeks.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If no recurrence of chronic renal insufficiency, discuss resumption of ICPi with patient after thorough discussion of risks and benefits.</p>\n</li>\n</ul>\n<p dir=\"ltr\"><strong>Grade 3-4:</strong></p>\n<p><span id=\"docs-internal-guid-0a217669-7fff-bbce-ab85-760154b2b031\"></p>\n<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Permanently discontinue ICPi.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider Consult nephrology consultation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Evaluate for other causes (recent IV contrast, medications, fluid status, etc).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider corticosteroids (initial dose of 1-2 mg/kg/d prednisone or equivalent).</p>\n</li>\n</ul>", "critical_actions_en": ""}, "about": {"formula_en": "<div dir=\"ltr\" align=\"left\">\n<table><colgroup><col width=\"258\" /><col width=\"190\" /><col /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Nephritis grade</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Creatinine level increase of &gt;0.3 mg/dL; creatinine 1.5-2.0x over baseline</p>\n</td>\n<td>\n<p dir=\"ltr\">G1</p>\n</td>\n<td>\n<p dir=\"ltr\"></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Creatinine 2-3x above baseline</p>\n</td>\n<td>\n<p dir=\"ltr\">G2</p>\n</td>\n<td>\n<p dir=\"ltr\"></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Creatinine &gt;3x baseline or &gt;4.0 mg/dL; hospitalization indicated</p>\n</td>\n<td>\n<p dir=\"ltr\">G3</p>\n</td>\n<td>\n<p dir=\"ltr\"></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Life-threatening consequences; dialysis indicated</p>\n</td>\n<td>\n<p dir=\"ltr\">G4</p>\n</td>\n<td>\n<p dir=\"ltr\"></p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>\n<p dir=\"ltr\">See Next Steps for details on management.</p>", "more_info_en": "", "evidence_based_medicine_en": "<p>Guidelines for IRAE in for renal&nbsp; toxicity (nephritis) were developed by a multidisciplinary, multi-organizational panel of experts in medical oncology based on a systematic review of the medical literature.</p>", "references_list": {"Original/Primary Reference": [{"href": "ttps://www.ncbi.nlm.nih.gov/pubmed/29442540", "text": "Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Nazli", "img": "", "lastName": "Dizman", "name": "Nazli Dizman, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Julie R. Brahmer", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Julie R. Brahmer, MSc, MD, is the co-director of the upper aerodigestive department at Johns Hopkins Medicine in Baltimore, MD. She is also a professor of oncology at Johns Hopkins Medicine. Dr. Brahmer\u2019s primary research is focused on treatment of lung cancer and mesothelioma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-julie-brahmer.png", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Brahmer+JR%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Criteria", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Creatinine level increase of >0.3 mg/dL; creatinine 1.5-2.0x over baseline", "value": 1}, {"label": "Creatinine 2-3x above baseline", "value": 2}, {"label": "Creatinine >3x baseline or >4.0 mg/dL; hospitalization indicated", "value": 3}, {"label": "Life-threatening consequences; dialysis indicated", "value": 4}], "name": "grading"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10389, "short_title_en": "IRAE for GI Toxicity - Hepatitis", "slug": "immune-related-adverse-events-gi-toxicity-hepatitis"}, {"calcId": 10383, "short_title_en": "IRAE for Lung Toxicity - Pneumonitis", "slug": "immune-related-adverse-events-lung-toxicity-pneumonitis"}, {"calcId": 10382, "short_title_en": "IRAE for Endocrine Toxicities - Hypothyroidism", "slug": "immune-related-adverse-events-endocrine-toxicities-hypothyroidism"}]}